What Happened?
Philadelphia, PA-based Passage-Bio Retired Eliseo Salinas as Chief Research and Development Officer
About the Company
Passage Bio was launched with the vision to be a first in class fully-integrated biotech company developing life transforming AAV-delivered in vivo therapeutics for the treatment of rare CNS diseases. In collaboration with the University of Pennsylvania Gene Therapy Program, Philadelphia-based Passage Bio plans to advance a portfolio of 5 rare disease indications in the neuro/CNS genetic space through IND-enabling studies using best-in-class AAV technology and know-how. Subsequently, Passage Bio will be responsible for all clinical development and will collaborate with Penn`s Orphan Disease Center to support these efforts.
About the Person
Eliseo Salinas is Chief Research and Development Officer at Passage Bio. Previously, Eliseo held various senior HR leadership roles in the industry.
Info Source
News
Short Profile